Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced a Board of Directors meeting scheduled for August 5, 2026. The primary agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. Concurrently, the company has closed its trading window for designated persons from July 1, 2026, until 48 hours after the results declaration, in compliance with SEBI (Prohibition of Insider Trading) Regulations. The notice is also available on the company's website.

Desai Shares & Stock Pvt Ltd has acquired 1356 equity shares of Bharat Parenterals Limited through open market transactions between June 1-25, 2026. This acquisition represents a 0.0197% stake, increasing the acquirer's total shareholding to 39.67%. The total share capital of Bharat Parenterals Limited remains unchanged at 6,89,19,630 equity shares.

Desai Shares and Stock Pvt Ltd, a promoter group entity, has acquired 1356 equity shares of Bharat Parenterals Limited through open market transactions. The acquisition occurred between June 1, 2026, and June 25, 2026. Following this transaction, Desai Shares and Stock Pvt Ltd's total shareholding in Bharat Parenterals Limited increased from 39.65% to 39.67%. The total equity share capital of the company remains unchanged at 68,91,963 equity shares.

Bharat Parenterals Ltd has filed a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, detailing a change in shareholding. Desai Shares and Stock Private Limited, a promoter group entity, acquired 1,356 equity shares. This acquisition resulted in a slight increase in their shareholding from 39.65% to 39.67%. The transaction was conducted on-market on June 25, 2026, with the shares acquired at a value of ₹18,06,434. The disclosure is made as per regulatory requirements concerning insider trading.

Bharat Parenterals Ltd has announced the closure of its trading window for dealing in equity shares, effective from July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain in effect until 48 hours after the declaration of the company's un-audited financial results (standalone and consolidated) for the quarter ended June 30, 2026. During this period, designated persons and their immediate relatives are prohibited from trading in the company's shares. The company will also facilitate the freezing of PANs of designated persons and their relatives at the depository portal. The date of the board meeting to approve these financial results will be intimated separately.

Bharat Parenterals Ltd has filed a disclosure under SEBI (PIT) Regulations, 2015, detailing a change in shareholding. Desai Shares and Stock Private Limited, a promoter entity, acquired 900 equity shares on June 3, 2026. This transaction increased their holding from 27,31,536 shares (39.63%) to 27,32,436 shares (39.65%). The acquisition was made on the open market via the BSE exchange. The disclosure was submitted on June 15, 2026.

Desai Shares and Stocks Pvt Ltd, a promoter group entity, has acquired 900 equity shares of Bharat Parenterals Limited through open market transactions. This acquisition, occurring between June 3 and June 15, 2026, increased their total shareholding from 39.63% to 39.64%. The total number of shares held by Desai Shares and Stocks Pvt Ltd is now 27,32,436.

Bharat Parenterals Ltd. announced the appointment of M/s. Chetan Gandhi & Associates as Cost Auditor and M/s. Dhruvik Parikh & Co. as Internal Auditor for the financial year 2026-27. The appointments were approved by the Board of Directors at their meeting held on May 18, 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board of Directors of Bharat Parenterals Ltd, in its meeting held on May 18, 2026, recommended a final dividend of ₹1 per equity share of ₹10 each (10%) for the financial year ended March 31, 2026. The dividend, subject to shareholder approval at the AGM and applicable tax deductions, will be credited/dispatched within 30 days from the AGM date. The board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and re-appointed the cost and internal auditors.

Bharat Parenterals Ltd approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1.00 per equity share (10%) for FY26, subject to shareholder approval at the AGM. They also re-appointed M/s. Chetan Gandhi & Associates as Cost Auditor and M/s. Dhruvik Parikh & Co. as Internal Auditor for FY27.